We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 3,738

Kann die Rückerstattung von Mehreinnahmen überhaupt durchgesetzt werden?
  • Streichenberg Attorneys at Law
  • Switzerland
  • September 25 2018

Die Verordnung über die Krankenversicherung (KVV) verpflichtet die Zulassungsinhaber zur Rückerstattu...

Pharmacovigilance in Mexico
  • Mexico, Global
  • September 3 2018

A structured guide to Pharmacovigilance in Mexico

Life Sciences: product regulation and liability in Mexico
  • Mexico, Global
  • September 3 2018

A structured guide to product regulation and liability laws in Mexico

Life Sciences: Compliance and enforcement in Switzerland
  • Bär & Karrer
  • Switzerland, Global
  • September 3 2018

A structured guide to compliance and dishonest practices in Switzerland

Pharmacovigilance in Italy
  • Avvocati Associati Franzosi Dal Negro Setti
  • Global, Italy
  • September 3 2018

A structured guide to Pharmacovigilance in Italy

CMS Allows Medicare Part D Indication-Based Formulary Design
  • Holland & Knight LLP
  • USA
  • August 30 2018

The Centers for Medicare and Medicaid Services (CMS) has just announced a significant shift in Medicare Part D formulary design to allow Part D

Overriding Patents - The Naloxone Dilemma
  • Workman Nydegger
  • USA
  • August 23 2018

With no end in sight to the ongoing, and widening, opioid epidemic in the United States, politicians, public health officials, and healthcare

Sick Leave Can Be Calculated Based on Average Shift Length
  • Jones Day
  • USA, Australia
  • August 21 2018

In October 2017, Mondelez Australia Pty Ltd ("Mondelez"), a chocolate manufacturing facility in Tasmania, sought approval of an EBA. Clause 24 of the

Dutch competition authority ACM starts sector inquiry into anti-rheumatism drugs
  • Taylor Wessing
  • Netherlands
  • August 21 2018

In a previous edition of Synapse we already informed you about the fact that the Dutch Authority for Consumer and Market ("ACM") announced in its

President Trump’s Drug Pricing Plan: What’s Next?
  • Manatt Phelps & Phillips LLP
  • USA
  • August 21 2018

The Administration’s drug pricing plan, “American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket